Your cart is currently empty!
Category: Chemotherapy
Daunorubicin
Description
This page contains brief details about the drug daunorubicin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Daunorubicin is an anti-cancer drug containing the active constituent daunorubicin. This chemotherapy medication belongs to the anthracycline class of drugs. It is used in the treatment of leukemia. In leukemia, the white blood cells produced in the bone marrow multiply uncontrolled and abnormally. Leukemia is associated with severe infection, extreme tiredness, and joint pain. It is necessary to inform your doctor if you have an infection, cardiac diseases, mouth ulcers, chickenpox or shingles (viral infection), fever, radiation treatment to the chest, kidney stones, and liver disorders.
Daunorubicin was first approved by the FDA in 1979 for the treatment of acute myeloid leukemia (AML). Since then, Daunorubicin has been approved for additional indications and formulations, including for the treatment of solid tumors and lymphomas. Like many chemotherapy drugs, it can cause side effects such as nausea, vomiting, hair loss, fatigue, and an increased risk of infection due to its effect on the immune system.
Mechanism of Action of Daunorubicin
The therapeutic effect of daunorubicin is to inhibit the growth and replication of cancer cells. As a chemotherapy medication, daunorubicin works by binding to DNA and interfering with its replication and transcription, ultimately leading to cell death. Doing so can help shrink tumors, prevent cancer from spreading to other parts of the body, and potentially cure cancer in some cases.
Uses of Daunorubicin
Daunorubicin is primarily used to treat acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. It can also be used to treat other types of cancer, including acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), lymphoma, and solid tumors such as breast and ovarian cancer.
Daunorubicin Dosage available
Daunorubicin is typically administered as an intravenous (IV) infusion or injection in a hospital or clinical setting by a healthcare provider. The exact dosing and frequency of administration will depend on the specific condition being treated and other individual factors, such as the patient’s age, weight, and overall health. If a dose is missed, it’s important to contact your healthcare provider as soon as possible to determine the appropriate course of action. Suppose the missed dose is discovered within a few hours of the scheduled time. In that case, your healthcare provider may recommend administering the missed dose as soon as possible while maintaining the usual interval between doses. However, if more than a few hours have passed since the missed dose, your healthcare provider may recommend skipping the missed dose and resuming the regular dosing schedule at the next scheduled time. It’s important not to double up on doses to make up for a missed one.
Rucaparib
Description
This page contains brief details about the drug rucaparib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Rucaparib is an anticancer drug that belongs to the class of medications called PARP (poly ADP-ribose polymerase) inhibitors. FDA approved this medicine on December 19, 2016, to treat certain types of cancers.
Mechanism of Action of Rucaparib
Rucaparib is an inhibitor of poly Adenosine diphosphate-ribose polymerase enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. It blocks an enzyme that repairs damaged DNA in the cancer cells, resulting in their death.
Uses of Rucaparib
Rucaparib is an orally available prescription drug. It is used to help maintain the response to other treatments for certain types of ovarian cancer, fallopian tube (a tube that transports eggs released by the ovaries to the uterus), and primary peritoneal (layer of tissue that lines the abdomen) cancer that has reoccurred in adults who have previously completely responded or partially responded to other chemotherapy treatments.
It is also used to treat certain types of cancer in people with specific gene (BRCA) changes who have received treatment with at least two other chemotherapy treatments. It is also indicated as maintenance therapy immediately after chemotherapy which has caused the tumor to shrink.
Rucaparib Dosage available
It is an orally available antineoplastic drug. The medicine is available as 200mg, 250mg, and 300mg tablets. Your doctor will decide the dose and duration of Rucaparib based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water.
Aprepitant
Description
This page contains brief details about the drug aprepitant, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
The U.S. FDA-approved Aprepitant to prevent nausea and vomiting due to chemotherapy on 26th March 2003.
Mechanism of Action of Aprepitant
Aprepitant capsule blocks the action of a natural substance called neurokinin in the brain that causes nausea and vomiting. This medicine reduces the severity of chemotherapy-induced nausea and vomiting.
Uses of Aprepitant
Aprepitant is used to prevent nausea and vomiting due to chemotherapy in adults and children of twelve years and older.
Aprepitant Dosage available
Swallow the Aprepitant capsule as a whole with water. Do not crush or chew the capsules. These capsules can be taken with or without food. Do not take more than recommended. If this medicine is prescribed, your physician will choose the dosage based on your medical condition because it differs for each person. Only stop taking Aprepitant if your doctor advises you to stop.
Granisetron
Description
This page contains brief details about the drug granisetron, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Granisetron is an antiemetic drug that belongs to the class 5-HT 3 receptor antagonists and is effective against nausea and vomiting. It was approved by the FDA on 25 July 1
Mechanism of Action of Granisetron
Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic (effective against vomiting and nausea) activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors, in turn, blocks the substance serotonin, a natural substance in the body that causes nausea and vomiting.
Uses of Granisetron
Granisetron is indicated to prevent nausea and vomiting associated with initial and repeated courses of emetogenic (a substance that causes vomiting) chemotherapy and radiation therapy. It is also used to treat and prevent nausea and vomiting in adults that may occur after surgery.
Granisetron Dosage available
Granisetron is a prescription generic drug available as an injectable solution, extended-release subcutaneous injection, transdermal patch, tablet, and oral solution. The oral dose is given 1 hour before chemotherapy, followed by 12 hours after chemotherapy to prevent chemotherapy-induced nausea and vomiting. The recommended injection dose is 10 mcg/kg intravenously 30 minutes before chemotherapy. Your doctor will decide the dose, frequency, and dosage based on the severity of the condition. To prevent radiation-induced nausea and vomiting, the recommended dose is given orally 1 hour before radiation therapy. To prevent postoperative nausea and vomiting, the recommended dose is given intravenously before induction of anesthesia. To treat postoperative nausea and vomiting, the recommended dose is given intravenously.
5FU GLS
Description
This page contains brief details about the drug fluorouracil, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Fluorouracil contains the active ingredient Fluorouracil. It belongs to a class of drugs called antimetabolites, which interfere with the genetic material (DNA and RNA) synthesis of rapidly dividing cancer cells, leading to their death. This medication is commonly used to treat breast, colorectal, stomach, esophagus, and pancreatic cancers. It can be administered in different ways, including through injection or as a cream.
Fluorouracil (5-fluorouracil or 5-FU) was first approved by the US Food and Drug Administration (FDA) in 1959 for treating colon and rectal cancer. Since then, it has been approved for treating other types of cancer, including breast, stomach, and pancreatic cancer. The drug is also approved in many other countries around the world. Over the years, many studies proved the effectiveness of fluorouracil in combination with other cancer treatments, and the drug continues to be an important chemotherapy medication for cancer patients.
Mechanism of Action of Fluorouracil
Fluorouracil work by interfering with the DNA and RNA synthesis of rapidly dividing cancer cells, leading to their death. It is an antimetabolite chemotherapy drug that mimics the structure of normal DNA and RNA building blocks. Still, its incorporation into DNA and RNA leads to errors in formation and causes damage to the DNA and RNA strands.
Uses of Fluorouracil
Fluorouracil is a chemotherapy medication commonly used to treat different types of cancer, including breast, colon, rectal, stomach, and pancreatic cancers. It works by interfering with the growth and division of cancer cells, ultimately causing them to die.
Fluorouracil Dosage available Fluorouracil is a medication typically administered under a healthcare provider’s supervision, usually in a hospital or clinic setting. The method of administration can vary depending on the type of cancer and the individual patient’s condition. The injection can be given in a vein (intravenous) or muscle (intramuscular) injection. If a patient misses a scheduled dose, they should contact their healthcare provider immediately to determine the next steps. Sometimes, the missed dose may be rescheduled, or a new treatment plan may be recommended. It is important to follow the healthcare provider’s instructions closely and not make any changes to the treatment plan without first consulting with them. Patients should never take a double dose to make up for a missed dose, as this can increase the risk of side effects and toxicity.